

Julien Seneschal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7726253/publications.pdf>

Version: 2024-02-01

158
papers

5,109
citations

81900

39
h-index

110387

64
g-index

165
all docs

165
docs citations

165
times ranked

6258
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors associated with perceived stress in patients with vitiligo in the ComPaRe e-cohort. Journal of the American Academy of Dermatology, 2022, 86, 696-698.	1.2	9
2	Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling. Journal of Investigative Dermatology, 2022, 142, 1194-1205.e7.	0.7	23
3	EczemaPartner " adapting a questionnaire to assess the impact of atopic dermatitis on partners of patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
4	Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice. British Journal of Dermatology, 2022, 186, 733-735.	1.5	3
5	Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo. British Journal of Dermatology, 2022, 187, 422-424.	1.5	6
6	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1578-1583.	2.4	11
7	The humanistic burden of vitiligo: a systematic literature review of quality of life outcomes. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1507-1523.	2.4	11
8	Correlation of nailfold capillaroscopy findings with history of digital ulcer on same finger: Results of SCLEROCAP study. Microvascular Research, 2022, 142, 104365.	2.5	2
9	Interleukin-1 β -Activated Microvascular Endothelial Cells Promote DC β -SIGN β -Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 1013-1026.	5.6	7
10	Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. British Journal of Dermatology, 2022, 187, 602-603.	1.5	6
11	An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1486-1496.	2.4	10
12	The harmful effects of aesthetic care: Dealing with new kinds of exogenous acne. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0
13	Alopecia areata: Recent advances and emerging therapies. Annales De Dermatologie Et De Venereologie, 2022, 149, 222-227.	1.0	5
14	Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 912-918.	2.4	5
15	An update on Vitiligo pathogenesis. Pigment Cell and Melanoma Research, 2021, 34, 236-243.	3.3	61
16	Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e301-e303.	2.4	3
17	Use of mind-body practices by patients with psoriasis: results from a study on 2562 patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e305-e307.	2.4	2
18	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27

#	ARTICLE	IF	CITATIONS
19	Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective. <i>Frontiers in Immunology</i> , 2021, 12, 613056.	4.8	19
20	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	2.4	24
21	Demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of vitiligo patients: a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e676-e679.	2.4	9
22	Development of a shared decision-making tool in vitiligo: an international study. <i>British Journal of Dermatology</i> , 2021, 185, 787-796.	1.5	10
23	Editorial: Immunology of Vitiligo. <i>Frontiers in Immunology</i> , 2021, 12, 711080.	4.8	4
24	Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with a high frequency of melanoma-infiltrating CXCR3 ⁺ resident memory CD8 ⁺ T cells and multiple chemokine pathways. <i>British Journal of Dermatology</i> , 2021, 185, 663-666.	1.5	1
25	Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1728-1734.	0.7	17
26	TGF β 2 promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1594-1603.	0.9	30
27	Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3194-3196.	5.7	31
28	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index ≤ 10 treated with biological agents: results from the French PsoBioTeq cohort. <i>British Journal of Dermatology</i> , 2021, 185, 1052-1054.	1.5	2
29	Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e-cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 36, 279.	2.4	2
30	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , 2021, 157, 474-484.	2.8	45
31	Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study. <i>JAAD International</i> , 2021, 5, 112-120.	2.2	10
32	Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme. <i>JAMA Dermatology</i> , 2021, 157, 1472.	4.1	5
33	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. <i>British Journal of Dermatology</i> , 2020, 182, 1423-1429.	1.5	14
34	Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1639-1646.	1.2	17
35	Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e74-e76.	2.4	53
36	NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1143-1153.e5.	0.7	32

#	ARTICLE	IF	CITATIONS
37	Eczema Herpeticum: Clinical and Pathophysiological Aspects. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 1-18.	6.5	47
38	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
39	ESDR Academy for Future Leaders in Dermatology: A Springboard for Career Achievement. <i>Journal of Investigative Dermatology</i> , 2020, 140, S187-S188.	0.7	0
40	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
41	Vitiligo, From Physiopathology to Emerging Treatments: A Review. <i>Dermatology and Therapy</i> , 2020, 10, 1185-1198.	3.0	29
42	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque psoriasis treated with biologics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	2.4	19
43	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e839-e842.	2.4	22
44	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	2.4	99
45	Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease. <i>JAAD Case Reports</i> , 2020, 6, 189-191.	0.8	5
46	Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2330-2338.	2.4	13
47	Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: A survey study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1188-1191.	1.2	8
48	Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1427-1434.e5.	0.7	12
49	Phenotype and function of circulating memory T cells in human vitiligo*. <i>British Journal of Dermatology</i> , 2020, 183, 899-908.	1.5	14
50	Is Hyperpigmentation in Systemic Sclerosis a Perivascular Dermal Tattoo?. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2308-2312.e2.	0.7	0
51	Type-1 cytokines regulate matrix metalloproteinase-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. <i>JCI Insight</i> , 2020, 5, .	5.0	31
52	Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 405-409.	2.4	12
53	Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 307-308.	3.8	8
54	Image Gallery: Jacquet papulo-erosive dermatitis in an adult. <i>British Journal of Dermatology</i> , 2019, 181, e145.	1.5	1

#	ARTICLE	IF	CITATIONS
55	Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e494-e495.	2.4	6
56	Low cardiovascular risk and poor quality of life associated with tobacco use and skin infections in adult atopic dermatitis: result of a French multicenter study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e451-e453.	2.4	4
57	An unusual presentation of Sutton's phenomenon presenting as halo cherry angioma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e464-e465.	2.4	0
58	Vitiligo, Associated Disorders and Comorbidities (Autoimmune-Inflammatory Disorders,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Td (I		3
59	Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies. , 2019, , 163-167.		0
60	Clinically Inflammatory Vitiligo and Rare Variants. , 2019, , 81-91.		2
61	Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight, 2019, 4, .	5.0	34
62	Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). Journal of the American Academy of Dermatology, 2019, 81, 1107-1114.	1.2	19
63	Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab. JAMA Dermatology, 2019, 155, 1312.	4.1	56
64	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	2.4	85
65	Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1921-1927.	2.4	26
66	GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. British Journal of Dermatology, 2019, 180, 647-656.	1.5	51
67	The impact of atopic dermatitis on sexual health. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 428-432.	2.4	36
68	Imbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo. Pigment Cell and Melanoma Research, 2019, 32, 588-592.	3.3	4
69	Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Experimental Dermatology, 2019, 28, 656-661.	2.9	26
70	Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients. Journal of the American Academy of Dermatology, 2019, 80, 478-484.	1.2	18
71	Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 435-443.	0.8	5
72	Cell delivery using microneedle devices: a new approach to treat depigmenting disorders. British Journal of Dermatology, 2018, 178, 588-589.	1.5	2

#	ARTICLE	IF	CITATIONS
73	Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2018, 85, 663-668.	1.6	23
74	Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2018, 85, 155-163.	1.6	31
75	Vitiligo-like lesions in patients receiving anti-CD95 programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, e17-e18.	1.2	13
76	Elevated total serum IgE in vitiligo might be protective for other autoimmune diseases. <i>British Journal of Dermatology</i> , 2018, 179, 987-988.	1.5	2
77	Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. <i>British Journal of Dermatology</i> , 2018, 179, 534-536.	1.5	40
78	Dermatite atopique: nouveaux physiopathologiques-cibles moléculaires. <i>Revue Française D'allergologie</i> , 2018, 58, 142-143.	0.2	0
79	Recurrent erysipelas of the face with hyperimmune reaction to group C streptococcus. <i>British Journal of Dermatology</i> , 2018, 179, 524-525.	1.5	0
80	Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 52-67.	6.5	155
81	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
82	Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3. <i>Journal of Investigative Dermatology</i> , 2018, 138, 355-364.	0.7	168
83	A case of lichenoid and pigmented drug eruption to acetazolamide confirmed by a lichenoid patch test. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 283-285.	3.8	4
84	Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. <i>British Journal of Dermatology</i> , 2018, 178, 650-658.	1.5	17
85	Inflammatory skin eruptions induced by anti-tumour necrosis factor- α therapy differ undeniably from psoriasis or eczema. <i>British Journal of Dermatology</i> , 2018, 178, 1007-1008.	1.5	0
86	Patient Burden is Associated with Alterations in Quality of Life in Adult Patients with Atopic Dermatitis: Results from the ECLA Study. <i>Acta Dermato-Venereologica</i> , 2018, 98, 713-714.	1.3	17
87	Inflammasome Activation Characterizes Lesional Skin of Folliculitis Decalvans. <i>Acta Dermato-Venereologica</i> , 2018, 98, 570-575.	1.3	11
88	In vitro models of vitiligo. , 2018, , 129-149.		0
89	OX40/OX40 axis impairs follicular and natural Treg function in human SLE. <i>JCI Insight</i> , 2018, 3, .	5.0	46
90	Vitiligo therapy: restoring immune privilege?. <i>Experimental Dermatology</i> , 2017, 26, 635-636.	2.9	3

#	ARTICLE	IF	CITATIONS
91	Vitiligo-like lesions occurring in patients receiving anti-programmed cell death ¹ therapies are clinically and biologically distinct from vitiligo. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 863-870.	1.2	128
92	Meeting report: Vitiligo Global Issues Consensus Conference Workshop – Outcome measurement instruments and Vitiligo International Symposium, Rome, Nov 30–Dec 3rd. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 436-443.	3.3	14
93	Delayed cutaneous hypersensitivity reactions to iodinated contrast media. <i>European Journal of Dermatology</i> , 2017, 27, 190-191.	0.6	5
94	MicroRNA-211 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1965-1974.	0.7	55
95	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <sc>TOPICOP</sc> score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1713-1719.	5.7	52
96	Respiratory infections associated with anti-TNF [±] agents. <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 375-381.	5.0	12
97	Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. <i>British Journal of Dermatology</i> , 2017, 177, 1367-1375.	1.5	75
98	Special Considerations in Children with Vitiligo. <i>Dermatologic Clinics</i> , 2017, 35, 229-233.	1.7	19
99	Anti-tumour necrosis factor [±] induced lupus erythematosus panniculitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e318-e319.	2.4	5
100	Azathioprine-induced rosacea. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e310-e311.	2.4	4
101	European dermatology forum S1 guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1581-1594.	2.4	79
102	European Dermatology Forum S1 guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1401-1424.	2.4	148
103	Reproducibility of capillaroscopic classifications of systemic sclerosis: results from the SCLEROCAP study. <i>Rheumatology</i> , 2017, 56, 1713-1720.	1.9	27
104	Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 28-40.	3.3	38
105	Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors. <i>Acta Dermato-Venereologica</i> , 2017, 97, 731-734.	1.3	13
106	Successful rapid subcutaneous desensitization to anakinra in a case of delayed-type hypersensitivity reaction. <i>British Journal of Dermatology</i> , 2016, 174, 1417-1418.	1.5	7
107	Antitumour necrosis factor- [±] therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. <i>British Journal of Dermatology</i> , 2016, 174, 667-670.	1.5	18
108	Clinical repigmentation patterns in paediatric vitiligo. <i>British Journal of Dermatology</i> , 2016, 175, 555-560.	1.5	14

#	ARTICLE	IF	CITATIONS
109	Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 379-382.	1.3	4
110	Pigmented lichenoid drug eruption: a new clinical presentation of interface dermatitis induced by anti-TNF alpha drugs. <i>European Journal of Dermatology</i> , 2016, 26, 633-634.	0.6	6
111	Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. <i>Rheumatology</i> , 2016, 55, 1664-1672.	1.9	58
112	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. <i>Immunity</i> , 2016, 45, 209-223.	14.3	73
113	<scp>DLQI</scp> as a major criterion for introduction of systemic agents in patients with mild psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1961-1964.	2.4	19
114	Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2784-2794.	5.6	42
115	A Score with a VESted Interest in Vitiligo. <i>Journal of Investigative Dermatology</i> , 2016, 136, 902-904.	0.7	0
116	Follicular vitiligo: A report of 8 cases. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1178-1184.	1.2	45
117	The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool. <i>Journal of Investigative Dermatology</i> , 2016, 136, 52-58.	0.7	83
118	New insights into immune mechanisms of vitiligo. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 44-54.	0.8	13
119	Living with vitiligo: results from a national survey indicate differences between skin phototypes. <i>British Journal of Dermatology</i> , 2015, 173, 607-609.	1.5	47
120	Atopic Dermatitis Burden Scale for Adults: Development and Validation of a New Assessment Tool. <i>Acta Dermato-Venereologica</i> , 2015, 95, 700-705.	1.3	27
121	OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. <i>Immunity</i> , 2015, 42, 1159-1170.	14.3	189
122	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. <i>Haematologica</i> , 2015, 100, 1086-95.	3.5	37
123	Comment: the mystery of melanocyte demise in vitiligo. <i>Experimental Dermatology</i> , 2015, 24, 260-261.	2.9	3
124	A Th2 Cytokine Interleukin-31 Signature in a Case of Sporadic Lichen Amyloidosis. <i>Acta Dermato-Venereologica</i> , 2015, 95, 223-224.	1.3	9
125	Long-Term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study. <i>Acta Dermato-Venereologica</i> , 2014, 96, 802-6.	1.3	4
126	Langerin + Dermal DC, but Not Langerhans Cells, Are Required for Effective CD8-Mediated Immune Responses after Skin Scarification with Vaccinia Virus. <i>Journal of Investigative Dermatology</i> , 2014, 134, 686-694.	0.7	37

#	ARTICLE	IF	CITATIONS
127	Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell and Melanoma Research, 2014, 27, 398-407.	3.3	118
128	Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra. Journal of the American Academy of Dermatology, 2014, 71, e53-e56.	1.2	25
129	Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study. Journal of the American Academy of Dermatology, 2014, 70, 1146-1149.	1.2	66
130	Accelerating bleaching in vitiligo: balancing benefits versus risks. Experimental Dermatology, 2014, 23, 879-880.	2.9	4
131	Targeting iHSP 70 in vitiligo: a critical step for cure?. Experimental Dermatology, 2013, 22, 570-571.	2.9	6
132	Development and validation of the VSCOR for scoring Koebner's phenomenon in vitiligo/nonsegmental vitiligo. Pigment Cell and Melanoma Research, 2013, 26, 402-407.	3.3	26
133	Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. British Journal of Dermatology, 2013, 168, 756-761.	1.5	57
134	Halo Nevi Association in Nonsegmental Vitiligo Affects Age at Onset and Depigmentation Pattern. Archives of Dermatology, 2012, 148, 497.	1.4	41
135	Exogenous Inflammatory Acne due to Combined Application of Cosmetic and Facial Rubbing. Dermatology, 2012, 224, 221-223.	2.1	12
136	Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series. Dermatology, 2012, 224, 369-373.	2.1	39
137	Alternative Procedure to Allow Continuation of Dapsone Therapy despite Serious Adverse Reaction in a Case of Dapsone-Sensitive Erythema Elevatum Diutinum. Dermatology, 2012, 224, 115-119.	2.1	9
138	Cutaneous Drug Eruptions Associated with the Use of Biologics and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases. Chemical Immunology and Allergy, 2012, 97, 203-216.	1.7	3
139	Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. British Journal of Dermatology, 2012, 167, 490-495.	1.5	55
140	Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells. Immunity, 2012, 36, 873-884.	14.3	381
141	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. British Journal of Dermatology, 2012, 167, 1138-1144.	1.5	91
142	Follicular vitiligo: a new form of vitiligo. Pigment Cell and Melanoma Research, 2012, 25, 527-529.	3.3	20
143	Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. British Journal of Dermatology, 2012, 166, 539-544.	1.5	43
144	Biologics in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2012, 10, 174-178.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Biologika bei atopischer Dermatitis. JDDG - Journal of the German Society of Dermatology, 2012, 10, 174-179.	0.8	7
146	Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. British Journal of Dermatology, 2012, 167, 417-423.	1.5	42
147	Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. British Journal of Dermatology, 2011, 165, 44-49.	1.5	46
148	Loss of epidermal hypoxia-inducible factor-1 α accelerates epidermal aging and affects re-epithelialization in human and mouse. Journal of Cell Science, 2011, 124, 4172-4183.	2.0	76
149	Platelet CD154 Potentiates Interferon- γ Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus. Science Translational Medicine, 2010, 2, 47ra63.	12.4	174
150	Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case-control study. Journal of Hepatology, 2010, 53, 1035-1040.	3.7	92
151	Inflammatory Vitiligo. , 2010, , 99-105.		3
152	A case of primary erythralgia with encephalopathy. Journal of Neurology, 2009, 256, 1767-1768.	3.6	5
153	Cytokine imbalance with increased production of interferon- γ in psoriasiform eruptions associated with antitumour necrosis factor- α treatments. British Journal of Dermatology, 2009, 161, 1081-1088.	1.5	147
154	Oral erosive lichen planus and Good's syndrome: just a coincidence or a direct link between the two diseases?. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 506-507.	2.4	13
155	The Use of Patch Tests in Determining Hypersensitivity to Etanercept and Infliximab-Reply. Archives of Dermatology, 2008, 144, 1071.	1.4	3
156	Psoriasiform Drug Eruptions Under Anti-TNF Treatment of Arthritis are Not True Psoriasis. Acta Dermato-Venereologica, 2007, 87, 77-80.	1.3	22
157	Psoriasiform Eruptions During Anti-TNF Treatment: Psoriasis or Not?. Archives of Dermatology, 2007, 143, 1593-5; author reply 1595.	1.4	16
158	Pancytopenia induced by low-dose methotrexate in a haemodialysis patient treated for bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1135-1136.	2.4	11